Moreover, aggressive cancers including leukemia and pancreatic adenocarcinomas exhibit significant upregulation of HBEGF (Figure S7, Supporting Information), warranting further investigations to assess HP‐NP clinical relevance beyond brain tumors. This evidence concerns the gene HBEGF and pancreatic adenocarcinoma.